Certolizumab pegol in active rheumatoid arthritis

Affiliations

¹ Division of Rheumatology and Clinical Immunology, Division of Pediatric Rheumatology, University of Pittsburgh, Children's Hospital, PA, USA. aarat.patel@chp.edu

Comment

Aarat M Patel et al. Curr Rheumatol Rep. 2009 Oct.

. 2009 Oct;11(5):311-2.

doi: 10.1007/s11926-009-0056-7.

¹ Division of Rheumatology and Clinical Immunology, Division of Pediatric Rheumatology, University of Pittsburgh, Children's Hospital, PA, USA. aarat.patel@chp.edu

No abstract available

Comment on

Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Keystone E, Heijde Dv, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. Keystone E, et al. Arthritis Rheum. 2008 Nov;58(11):3319-29. doi: 10.1002/art.23964. Arthritis Rheum. 2008. PMID: 18975346 Clinical Trial.

1. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–1939. - PubMed
1. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400–1411. - PubMed
1. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250. - PubMed
1. Smolen J, Landewé RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009;68:797–804. - PMC - PubMed
1. Flcischmann R, Vencovsky J, van Vollenhoven R, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis. 2009;68:805–811. - PMC - PubMed